Dyadic International (DYAI) Retained Earnings (2017 - 2026)
Dyadic International (DYAI) posted Retained Earnings of $113.9 million for Q1 2026, up 221.86% sequentially from -$93.5 million in Q4 2025, and up 229.24% YoY from $34.6 million in Q1 2025.
Dyadic International (DYAI) Retained Earnings (2017 - 2026) Analysis & Trends
Dyadic International has reported Retained Earnings for 10 years, with the latest figure at $113.9 million in Q1 2026.
- Quarterly Retained Earnings rose 229.24% year-over-year to $113.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.9 million (up 229.24% YoY) and the FY2025 annual result came in at -$93.5 million, down 186.98% from the prior year.
- Retained Earnings climbed to $113.9 million in Q1 2026 per DYAI's latest filing, from -$93.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at $101.5 billion in Q1 2022 and troughed at -$93.5 million in Q4 2025.
- A 5-year average of $6.0 billion and a median of -$73.5 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings surged 188204.79% in 2022, then sank 186.98% in 2025.
- Over 5 years, Retained Earnings stood at -$73.5 million in 2022, then soared by 242.95% to $105.0 million in 2023, then grew by 2.28% to $107.4 million in 2024, then tumbled by 186.98% to -$93.5 million in 2025, then surged by 221.86% to $113.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $113.9 million, -$93.5 million, and $113.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 113.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113.88 Mn |
| Dec 31, 2025 | -93.45 Mn |
| Sep 30, 2025 | 113.37 Mn |
| Jun 30, 2025 | -89.91 Mn |
| Mar 31, 2025 | -88.11 Mn |
| Dec 31, 2024 | 107.44 Mn |
| Sep 30, 2024 | -84.54 Mn |
| Jun 30, 2024 | -84.33 Mn |
| Mar 31, 2024 | -82.29 Mn |
| Dec 31, 2023 | 105.04 Mn |
| Sep 30, 2023 | 104.75 Mn |
| Jun 30, 2023 | -76.59 Mn |
| Mar 31, 2023 | -74.44 Mn |
| Dec 31, 2022 | -73.48 Mn |
| Sep 30, 2022 | -71.34 Mn |
| Jun 30, 2022 | 101.98 Mn |
| Mar 31, 2022 | 101.52 Bn |
| Dec 31, 2021 | -63.75 Mn |
| Sep 30, 2021 | 100.32 Mn |
| Jun 30, 2021 | -57.82 Mn |